MPSYF News and Press, Morphosys Ag Ord From 11/03/22

Presentations - including four oral sessions - feature data supporting the potential benefit of first-line therapy for pelabresib in myelofibrosis and tafasitamab in diffuse large B-cell lymphoma Data add to the growing confidence in MorphoSys' pipeline and its pivotal trials BOSTON...

The findings, including encouraging preliminary efficacy data in various tumor types, were presented during the 34th EORTC-NCI-AACR Symposium PLANEGG/MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that preliminary results from th...

PLANEGG / MUNICH, GERMANY / ACCESSWIRE / October 27, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announced today that its licensing partner, GSK plc (GSK), provided an update on the ContRAst phase III program for otilimab as a potential treatment of moderate to severe rheumatoid arthritis (R...

MorphoSys ( OTCPK:MPSYF ) ( NASDAQ: MOR ) lowered its FY22 outlook for cancer drug Monjuvi' U.S. net product sales and provided preliminary Q3 sales figures. Q3 Preliminary Monjuvi (tafasitamab-cxix) U.S. net product sales are $22.2M (€21.9M). For t...

MorphoSys Reports Preliminary Q3 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022 Preliminary Q3 2022 Monjuvi U.S. net product sales of US$ 22.2 million (€ 21.9 million) Anticipated full year 2022 Monjuvi U.S. net product sales of approximately US$ 90 million...

MorphoSys AG (MOR) Q2 2022 Earnings Conference Call August 4, 2022 08:00 AM ET Company Participants Julia Neugebauer - IR Jean-Paul Kress - CEO Malte Peters - Chief Research & Development Officer Sung Lee - CFO Joseph Horvat - U.S. General Manager ...

Conference Call Alert PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 28, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) will publish its results for the second quarter and first half year 2022 results on August 3, 2022 at 10:00 pm CEST (9:00 pm BST; 4:00 pm EDT). MorphoSys' Management tea...

Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million) Update of financial guidance range for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 million) Update of R&D expense guidance (now € 275 to € 300 million) f...

Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014 Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million) Update of financial guidance ranges for 2022 Monjuvi U.S. net product sales (now ...

Unofficial sources said Joincare would seek to raise around $300 to $400 million. META Pharma of Shenzhen raised $15 million in Seed and Pre-A rounds to fund its immunometabolism-based small-molecule drug discovery operations. CANbridge, a Beijing-Cambridge MA rare disease/rare on...